Shots:

• As per the amended agreement- Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra- following the closing of Sierra’s qualified financing. In Aug’2018- Sierra acquired Gilead’s Momelotinib for $3M up front- $195M milestones and royalties on sales
• Additionally- Sierra and Gilead Sciences would sign a securities purchase agreement- under which Gilead will receive 7.5% shares of Sierra’s common stock along with warrant to purchase its common stock for an additional 7.5% shares
• Momelotinib is a JAK1- JAK2 & ACVR1 inhibitor- potentially used for the treatment of myelofibrosis with the anticipated onset of P-III MOMENTUM study in the coming months

Click here to­ read full press release/ article 

Ref: PRNewswire | Image:Gilead